Nicolas Michoux1, Bertrand Tombal2, Jean-Pascal Machiels3, Frederic Lecouvet1
1RDGN, Universit Catholique de Louvain, Brussels, Belgium; 2FYCL, Universit Catholique de Louvain, Brussels, Belgium; 3ONCO, Universit Catholique de Louvain, Brussels, Belgium
Using dynamic contrast-enhanced magnetic resonance imaging with a pharmacokinetic modeling of the data, the monitoring of the effects of anti-cancer therapy on bone metastases of prostate cancer during the course of the therapy becomes feasible. Ten patients scheduled to receive hormonotherapy or Taxotere therapy were imaged on a 1.5T MR scanner within one week before, 7 and 30 days after initial treatment. Perfusion maps based on Ktrans, ve and vp parameters were reconstructed. Complex changes reflecting either a decrease with a homogenization of the perfusion or an increase with a heterogenization of the perfusion, were observed in responders to therapy.